ClinicalTrials.gg
RecruitingNCT07127978PROVIDUSUpdated Jul 2, 2026

A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

An observational study in Duchene Muscular Dystrophy, sponsored by ITF Therapeutics LLC. Recruiting at 9 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by ITF Therapeutics LLC (part of Italfarmaco) · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Planned enrollment
13th of 55
300 · median 75
Started
2025
with 9 others
Observational
55 of 233
16 open now
Primary completion
2030-06
later than 47 of 59 live
Registered
218th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 13th largest by planned enrollment of the 55 observational ones that give a count, is one of 10 that started in 2025, is one of 55 observational ones, reaches primary completion later than 47 of the 59 other live ones, and was the 218th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.

Read the detailed description

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that leads to progressive muscle degeneration and weakness. Givinostat, an oral histone deacetylase inhibitor, was approved by the FDA in March 2024 for treatment of DMD in patients aged 6 years and older, regardless of mutation type.

Study participation will not influence the course of treatment in any way (including other treatments for DMD), and no treatment will be provided as part of this study. All assessments are intended to be performed at the time of a routine clinical care visit according to clinical practice, and data will be extracted from the medical records.

The FDA is requiring a post-marketing prospective study be conducted for a minimum of 5 years to characterize the incidence, frequency, and severity of thrombocytopenia and serious events of bleeding in patients with DMD treated with oral givinostat in routine clinical practice.

This study is designed as a prospective, observational study to assess safety (including evaluation of AEs of special interest [AESIs]) and effectiveness, in patients with DMD newly initiating oral givinostat as part of routine clinical care in the US in a real-world population. The study will assess AESIs noted above, as well as serious adverse events (SAEs), gastrointestinal (GI) AEs, and dehydration as a sequela to GI AEs. Real-world-treatment patterns of DMD treatments (corticosteroids, exon skipping oligonucleotides and gene therapy) prior to and after givinostat initiation, including treatment duration, and treatment combinations, will be described. Effectiveness evaluations will characterize motor function, quality of life, and activities of daily living in DMD patients treated with givinostat.

The study will enroll 300 participants (180 non-ambulatory and up to 120 ambulatory patients). Participants will be followed for at least two years, with data collected during routine clinical visits. Assessments include lab parameters (e.g., platelet counts, triglycerides), cardiac and pulmonary function, patient-reported outcomes, and motor function scales such as the North Star Ambulatory Assessment (NSAA) and Performance of Upper Limb (PUL) scale.

03

Conditions studied

  • Duchene Muscular Dystrophy

Keywords

  • DMD
  • DUVYZAT
  • U.S study
  • duchenne muscular dystrophy
  • givinostat
  • non-interventional study
  • pediatric neuromuscular disease
  • rare disease
  • quality of life
  • effectiveness
  • post-marketing requirement
  • safety
  • motor function
  • muscular dystrophy
  • standard of care
  • real-world evidence
  • observational study
  • post-marketing study
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will be conducted in the US and plans to enroll 300 patients diagnosed with DMD and treated with givinostat as part of their routine clinical care. Patients will be recruited from expert centers treating DMD patients with specialists in neuromuscular conditions who are routinely involved in the care and treatment of patients with DMD, some of whom would have already gained experience with givinostat.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of any gender at least 6 years of age, diagnosed with DMD (according to genetic test) and have received a prescription for oral givinostat in accordance with the USPI.
  • Patient has provided (and assent when applicable) for participation in the study.
  • Patient's index date (first date of givinostat treatment) is no more than 6 months prior to signing of informed consent.
  • Patient has the required data available (DMD diagnosis, givinostat administration [dose and schedule], laboratory results [hematology and triglycerides]) for addressing the study objectives for the period between index date and study entry (for patients enrolled after the index date).

Exclusion criteria

Exclusion Criteria:

  • Patient previously received givinostat (commercial or product) and permanently discontinued treatment or patient started commercial givinostat for > 6 months before signing of .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ambulatory

    Ambulatory is defined as being able to complete the 10-meter Walk-Run (10mWR) test within 30 seconds without an assistive device. This cohort will include up to 120 patients who are ambulatory prior to starting givinostat treatment. Within this cohort , 95 patients must have had prior use or a referral for concomitant use of dystrophin-enhancing therapy (DET), such as exon skipping oligonucleotides or gene therapy. Enrollment is capped at 25 patients without prior or referred DET use.

  • Non-Ambulatory

    Non-ambulatory status is determined by inability to perform the 10mWR test as defined above. This cohort will include approximately 180 patients who are non-ambulatory prior to starting givinostat.

06

What researchers measure

Primary outcomes

  1. Characterize the incidence of thrombocytopenia / decreased platelet counts in DMD patients treated with oral givinostat

    Incidence rate of thrombocytopenia (per 100 patient years of observation time) post index date

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  2. Characterize the frequency of thrombocytopenia / decreased platelet counts in DMD patients treated with oral givinostat

    Frequency and incidence proportion (overall and by maximum severity) of thrombocytopenia

    Time frame: [Time Frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]

  3. Characterize severity of serious events thrombocytopenia / decreased platelet counts in DMD patients treated with oral givinostat

    Time to first thrombocytopenia event from index date

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  4. Characterize the incidence of serious events of bleeding in DMD patients treated with oral givinostat

    Incidence rate of serious bleeding events (per 100-patient years of observation time) post index date

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  5. Characterize the frequency of serious events of bleeding in DMD patients treated with oral givinostat

    Frequency and incidence proportion (overall and by maximum severity) of serious bleeding events

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  6. Characterize the severity of serious events of bleeding in DMD patients treated with oral givinostat

    Time to first serious bleeding event from index date

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

Secondary outcomes

  1. Characterize the incidence of other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat

    Incidence rates of each AESI (per 100-patient years of observation time) post index date as well as the incidence proportion of AESIs resulting in dose modifications or givinostat discontinuation

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  2. Characterize the frequency other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat

    Frequency and incidence proportion (overall and by maximum severity) of each AESI

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  3. Characterize the severity of other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat

    Time to first event of each AESI from index date

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  4. Characterize the incidence of all serious adverse events (SAEs) in DMD patients treated with oral givinostat

    Incidence rates of SAEs (per 100-patient years of observation time) post index date by SOC and PT within SOC, and the number of SAEs per patient.

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  5. Characterize the frequency of all serious adverse events (SAEs) in DMD patients treated with oral givinostat

    Frequency and incidence proportion (overall and by maximum severity) of SAEs (by system organ class \[SOC\] and preferred term \[PT\] within SOC), and the frequency and incidence proportion of SAEs resulting in dose modifications or givinostat discontinuation.

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  6. Characterize the incidence of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat

    Incidence rates of GI AEs (per 100-patient years of observation time) post index date by PT.

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  7. Characterize the frequency of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat

    Frequency and incidence proportion (overall and by severity) of GI AEs (by PT), and frequency and incidence proportion of GI AEs resulting in dose modifications or givinostat discontinuation.

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  8. Characterize the severity of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat

    Number of GI AEs per patient

    Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)

  9. Characterization of hematology laboratory parameters

    Change from baseline hematology laboratory parameters over time

    Time frame: From baseline through end of study (up to 5 years)

  10. Characterization of triglyceride laboratory parameters

    Change from baseline triglyceride laboratory parameters over time

    Time frame: From baseline through end of study (up to 5 years)

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2030, 56 months after the start.

Of 63 observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 120. This study's planned 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Aug 17, 2025
StartActual
Oct 23, 2025
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jul 30, 2030
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07127978
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
Oct 23, 2025
Primary completion
Jun 30, 2030 (estimated)
Completion
Jul 30, 2030 (estimated)
Last update
Jul 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion